Patents with clinically indistinguishable clinical presentation of fatal infantile hypertrophic cardiomyopathy had mutations in the mitochondrial alanyl-tRNA synthetase 2 (AARS2) gene (Götz et al., 2011). This evidence concerns the gene AARS2 and Mitochondrial disease with hypertrophic cardiomyopathy.